Ulcerative Colitis (UC) has a relapsing–remitting disease course. Sparing use of oral corticosteroids (CS) ≥30 mg/day, as mono or combination therapy, are generally reserved for rapid relief of symptoms and induction of remission to achieve optimal therapeutic response. This analysis aimed to compare patient profiles of adult and pediatric patients newly diagnosed with UC who use ≥30 mg/day CS in a real world setting.